NICE recommends broader use for second SGLT2 inhibitor in chronic kidney disease

Empagliflozin (Jardiance) is set to be available for routine NHS prescribing in patients with chronic kidney disease (CKD), including some people without diabetes.

by Chloe Harman

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription and registration options.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Take a 30-day trial

  • Join MIMS now and pay nothing for the first 30 days

Sign Up